Broad-spectrum anti-tumor double-plasmid reproducible DNA vaccine

Abstract

The invention discloses a broad-spectrum anti-tumor double-plasmid reproducible DNA vaccine. Active ingredients of the broad-spectrum anti-tumor double-plasmid reproducible DNA vaccine comprise a tumor antigen compound gene-carrying anti-tumor antigen replicon DNA vaccine pSVK-CACA and a tumor blood vessel compound gene-carrying anti-tumor blood vessel replicon DNA vaccine pSVK-CAVE, wherein the tumor antigen compound gene-carrying anti-tumor antigen replicon DNA vaccine pSVK-CACA and the tumor blood vessel compound gene-carrying anti-tumor blood vessel replicon DNA vaccine pSVK-CAVE are constructed by using a replicon DNA vaccine carrier pSVK as a starting carrier. The broad-spectrum anti-tumor double-plasmid reproducible DNA vaccine provides a new choice for anti-tumor active immunity treatment and has a broad application prospect.

Description

technical field [0001] The invention belongs to the field of biotechnology, and in particular relates to a broad-spectrum anti-tumor double-plasmid replicable DNA vaccine. Background technique [0002] Overview of Therapeutic Vaccines [0003] Therapeutic tumor vaccine is an important technical means to prevent and treat the recurrence and metastasis of malignant tumors. It has developed rapidly in recent years. In 2010, PROVENGE⑧ (sipuleucel-T) became the first cell vaccine approved for clinical use for the treatment of hormone-resistant metastatic disease. prostate cancer. Following preventive vaccines, therapeutic vaccines have emerged in the field of international vaccine research at present, and have become a hot spot in the development of international biotechnology drugs. Therapeutic vaccines can induce specific immune responses in diseased individuals by reawakening the body's immune response to target antigens, clearing pathogens or abnormal cells, and treating di...

AI Technical Summary

Problems solved by technology

However, anti-angiogenesis active immunotherapy still has the following shortcomings: ①Tumor tissue may use other non-VEGF signaling pathways to induce neovascularization or use angiogenesis mimicry (that is, tumor cells mimic and replace endothelial cells to form a lumen-like structure) continue to get blood supply

② Anti-angiogenesis therapy can only inhibit the growth of tumor tissue in theory, and anti-angiogenesis alone cannot completely eradicate tumor cells

③ Anti-angiogenic therapy may cause adverse reactions such as hypertension and cardiovascular embolism, and it will also have a certain impact on normal wound healing and changes in women's menstrual cycle

Images